RevBio announced that it has received a strategic investment from Pacific Dental Services (PDS) to support the clinical development of its bone adhesive biomaterial for implant dentistry. Based in Irvine, California, PDS was founded in 1994 and is one of the leading dental support organizations in the U.S. with over 900 dental practices in 25 states. PDS has been on the Inc. 5000 list of the fastest growing private companies in America 14 times.
RevBio is currently in the clinical stage of development for its regenerative adhesive biomaterial for stabilizing dental implants. Most dental implants cannot be placed immediately after a tooth is removed due to accident, tooth decay, or gum disease. Instead, the current standard of care consists of multiple surgical and follow-up office visits to restore a patient’s dentition with dental implant supported prosthetic crowns. Based on company surveys, approximately 2.1 million implants are placed per year in the U.S. into initially unstable tooth extraction sites that could benefit from the use of TETRANITE.
This translates to approximately 38% of all implants placed per year in the United States. The use of the TETRANITE biomaterial will help reduce the duration and complexity of these dental implant procedures, lessen patient pain and recovery time, and reduce the overall cost of care thereby providing greater patient access for the treatment of tooth loss.
“We are very excited to partner with Pacific Dental Services, a company that clearly sees the value of the TETRANITE regenerative bone adhesive technology for improving the current standard of care for dental implant placement,” said Grayson Allen, CFO/COO of RevBio. “Our aim is to make dental implant procedures more predictable and save both patients and clinicians significant time by immediately stabilizing dental implants and accelerating treatment through the use of our unique biomaterial. This represents the first in a pipeline of dental products we are developing from the TETRANITE technology.”
“RevBio fits perfectly into our growing portfolio of investments in innovative technologies and companies that are developing next-generation materials and solutions for improving the delivery of dental care,” said Daniel Burke, chief enterprise strategy officer and general counsel for Pacific Dental Services. “We believe the TETRANITE technology holds great promise in improving the clinical experience for patients in need of implant dentistry.”
RevBio is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market.
RevBio’s TETRANITE technology platform is not yet approved for commercial use.
About Pacific Dental Services
Founded in 1994, Pacific Dental Services (PDS) is one of the country’s leading dental support organizations, providing supported autonomy that enables dentists to concentrate on clinical excellence and the highest levels of cost-effective comprehensive patient care. PDS originated the Private Practice+ model to enable dentists to focus on their passion: serving patients. PDS also pioneered the concept of modern dentistry so that dentists are equipped to combine advances in the latest technology with the best operational practices and procedures, highly skilled support staff and a commitment to ongoing training and education.
PDS continues to grow, and currently supports more than 2,700 dentists in over 900 dental offices across 25 states. PDS-supported dentists aim to be the provider of choice in all the markets they serve and to develop Patients for Life. For more information, visit us at pacificdentalservices.com or follow us on Facebook: @pacificdentalservices, Instagram: @pacific.dental, LinkedIn: @pacific-dental-services, Twitter: @pacificdental, and YouTube: @pacificdentaltv.